A Randomized, Open Label, Multi-Center, Phase 3 Efficacy Study of Sub-Q Abatacept in Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)
Clinical Trial Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
April 3, 2019
End Date
October 31, 2025
Awarded By
Bristol-Myers Squibb Company
Start Date
April 3, 2019
End Date
October 31, 2025